Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn, J Baselga - Journal of clinical oncology, 2003 - ascopubs.org
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family
that is abnormally activated in many epithelial tumors. Receptor activation leads to …
that is abnormally activated in many epithelial tumors. Receptor activation leads to …
Issues and progress with protein kinase inhibitors for cancer treatment
J Dancey, EA Sausville - Nature reviews Drug discovery, 2003 - nature.com
Identification of the key roles of protein kinases in cancer has led to extensive efforts to
develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 …
develop kinase inhibitors for the treatment of a wide range of cancers, and more than 30 …
Developing inhibitors of the epidermal growth factor receptor for cancer treatment
V Grunwald, M Hidalgo - Journal of the National Cancer Institute, 2003 - academic.oup.com
Progress in identifying and understanding the molecular and cellular causes of cancer has
led to the discovery of anomalies that characterize cancer cells and that represent targets for …
led to the discovery of anomalies that characterize cancer cells and that represent targets for …
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
EEW Cohen, F Rosen, WM Stadler… - Journal of clinical …, 2003 - ascopubs.org
Purpose: The epidermal growth factor receptor (EGFR) is a mediator of squamous cell
carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active …
carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active …
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
SS Sridhar, L Seymour, FA Shepherd - The lancet oncology, 2003 - thelancet.com
Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer
(NSCLC) is the leading cause of cancer-related death in men and women with overall cure …
(NSCLC) is the leading cause of cancer-related death in men and women with overall cure …
Targeting HER1/EGFR: a molecular approach to cancer therapy
C Arteaga - Seminars in oncology, 2003 - Elsevier
The varying efficacy and toxicity of traditional cancer therapies has driven the development
of novel target-based agents. Members of the HER (Human Epidermal Receptor) family, in …
of novel target-based agents. Members of the HER (Human Epidermal Receptor) family, in …
Targeting the epidermal growth factor receptor in non-small cell lung cancer
RS Herbst, PA Bunn Jr - Clinical cancer research, 2003 - AACR
Fifteen% or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …
current standard of care for patients with locally advanced or metastatic NSCLC is systemic …
Epidermal growth factor receptor as a therapeutic target in colorectal cancer
RB Cohen - Clinical colorectal cancer, 2003 - Elsevier
The epidermal growth factor receptor (EGFR) is widely expressed in advanced colorectal
cancers (CRCs), and higher levels of EGFR are inversely related to survival in these …
cancers (CRCs), and higher levels of EGFR are inversely related to survival in these …
Targeting epidermal growth factor receptor in head and neck cancer
AC Ford, JR Grandis - Head & Neck: Journal for the Sciences …, 2003 - Wiley Online Library
It is well known that growth factors play an important role in normal cell proliferation by
means of stimulation of growth factor receptors located on the surface of cells. Tumor cells …
means of stimulation of growth factor receptors located on the surface of cells. Tumor cells …
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice
CL Arteaga, J Baselga - Clinical cancer research, 2003 - AACR
There is an increased perception that current chemotherapeutic drugs have almost reached
a ceiling as systemic anticancer therapies. In great part because of their unpredictable side …
a ceiling as systemic anticancer therapies. In great part because of their unpredictable side …